Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Inhaled insulins Ghosh S; Collier APostgrad Med J 2007[Mar]; 83 (977): 178-81As a result of knowledge gained from the management of asthma with inhalers and nebulisers, pulmonary delivery devices for insulin have been developed. Particle size of the aerosol particularly influences drug delivery. Although several pharmaceutical companies are developing different systems, Pfizer have launched the first inhaled insulin (Exubera). Clinical trials have taken place in patients with both type 1 and type 2 diabetes, but have shown similar glucose control as subcutaneous insulin delivery. However, patient satisfaction does seem to be increased in patients taking inhaled insulins. Further studies are needed to investigate compliance, side-effect profiles, quality of life, long-term glycaemia control and cost effectiveness.|Administration, Inhalation[MESH]|Antibodies/analysis[MESH]|Cost-Benefit Analysis[MESH]|Diabetes Mellitus, Type 1/*drug therapy[MESH]|Diabetes Mellitus, Type 2/*drug therapy[MESH]|Humans[MESH]|Hypoglycemic Agents/*administration & dosage[MESH]|Insulin/*administration & dosage/immunology[MESH]|Patient Compliance[MESH]|Respiratory Function Tests[MESH]|Risk Factors[MESH]|Weight Gain[MESH] |
